• 1
    Huttenlocher A, Frieden IJ, Emery H. Neonatal onset multisystem inflammatory disease. J Rheumatol 1995; 22: 11713.
  • 2
    Kamel OW, van de Rijn M, LeBrun DP, Weiss LM, Warnke RA, Dorfman RF. Lymphoid neoplasms in patients with rheumatoid arthritis and dermatomyositis: frequency of Epstein-Barr virus and other features associated with immunosuppression. Hum Pathol 1994; 25: 63843.
  • 3
    Kamel OW, van de Rijn M, Hanasono MM, Warnke RA. Immunosuppression-associated lymphoproliferative disorders in rheumatic patients. Leuk Lymphoma 1995; 16: 3638.
  • 4
    Waldman M, Callen J. Self-resolution of Epstein-Barr virus-associated B-cell lymphoma in a patient with dermatomyositis following withdrawal of mycophenolate mofetil and methotrexate. J Am Acad Dermatol 2004; 51 Suppl 2: S12430.
  • 5
    Aksentijevich I, Nowak M, Mallah M, Chae JJ, Watford WT, Hofmann SR, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002; 46: 33408.
  • 6
    Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol 1997; 14: 814.
  • 7
    Tao J, Wasik MA. Epstein-Barr virus associated polymorphic lymphoproliferative disorders occurring in nontransplant settings. Lab Invest 2001; 81: 42937.
  • 8
    Tanner JE, Alfieri C. The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Transpl Infect Dis 2001; 3: 609.
  • 9
    Shroff R, Rees L. The post-transplant lymphoproliferative disorder: a literature review. Pediatr Nephrol 2004; 19: 36977.
  • 10
    Lee P, Beneck D, Weisberger J, Gorczyca W. Coexpression of CD43 by benign B cells in the terminal illeum. Appl Immunohistochem Mol Morphol 2005; 13: 13841.
  • 11
    Lovell DJ, Bowyer SL, Solinger AM. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum 2005; 52: 12836.
  • 12
    Janssen R, Verhard E, Lankester A, ten Cate R, van Dissel JT. Enhanced interleukin-1β and interleukin-18 release in a patient with chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 2004; 50: 332933.
  • 13
    Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004; 20: 31925.
  • 14
    Mullauer L, Gruber P, Sebinger D, Buch J, Wohlfart S, Chott A. Mutations in apoptosis genes: a pathogenetic factor for human disease. Mutat Res 2001; 488: 21131.
  • 15
    Chen W, Wang H, Srinivasa M, Srinivasula SM, Alnemri ES, Cooper NR. B Cell apoptosis triggered by antigen receptor ligation proceeds via a novel caspase-dependent pathway. J Immunol 1999; 163: 248391.